This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 adults will take the drugs until their disease gets worse or side effects become too severe. The goal is to see if…
Phase: PHASE1, PHASE2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated May 12, 2026 13:39 UTC